November 21st 2024
Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.
An Online Intervention Appears to Enhance Adherence to a Gluten-Free Diet in Celiac Disease
April 13th 2013A new study validates online delivery as an effective means of promoting dietary adherence in celiac disease, and this method may prove effective across diets for patients with obesity, metabolic syndrome, and diabetes.
Spinal Epidural Abscess in an Obese Woman With Back Pain
March 18th 2013An obese woman in her thirties with a history of fibromyalgia syndrome, depression, polycystic ovarian syndrome, and diabetes mellitus presents to her local emergency department with 1 week of gradually worsening midline back pain.
Novel Risk Factors Improve Prediction of Cardiovascular Disease in Intermediate-Risk Persons
February 12th 2013It has been predicted that costs for cardiovascular disease will increase to more than $1 trillion dollars annually in the US by 2030. If statins are effective in preventing heart disease, why are costs still rising?
Study Sheds Light on Wheat Sensitivity as an Emerging Clinical Entity
February 11th 2013Results suggest that wheat sensitivity is a true clinical entity worthy of further study, and that it is a heterogeneous condition with at least 2 distinct subtypes. How this will translate into clinical practice will be an evolving research area, but clinicians should not expect gluten avoidance to disappear as yet another food fad.
Some Reassurance About Proton Pump Inhibitors and Risk of Osteoporotic Fractures
February 11th 2013Despite limitations, this study lends some reassurance that risk of osteoporosis is not likely to overshadow the benefit of proton pump inhibitors in preventing recurrent peptic ulcer, esophageal reflux symptoms, and esophageal cancer risk.
Oroesophageal Candidiasis in a Patient With AIDS
January 18th 2013Topical treatment for oral candidiasis is not as effective when there is esophageal involvement. Topical treatments include nystatin, amphotericin B solution, and miconazole tablets. Systemic therapy given orally includes the azoles, of which fluconazole remains the most effective commonly prescribed. Voriconazole is effective against some resistant strains of Candida. Echinocandins, a newer class of drugs, inhibit cell wall synthesis.
Emphysematous Cholecystitis Caused by Clostridium perfringens With Hematogenous Spread to the Hip
November 2nd 2012Emphysematous cholecystitis is a rare condition that is the result of infection with C perfringens and other gas-producing organisms including Escherichia coli, Bacteroides fragilis, and Klebsiella species.